NIH-Sponsored Study Compares BEAR Implant to ACL Reconstruction for Complete ACL TearsWESTBOROUGH, Mass.--(BUSINESS WIRE)--#ACLrepair--Miach Orthopaedics, Inc., a company transforming the…
In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease…
Includes Conduit’s first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658Patents derived…
Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved No new PTSD…
TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase…
PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and…
FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approvalTividenofusp alfa is designed to deliver…
ARLINGTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research,…
8 of 9 participants (89%) treated in the 240mg and 360mg single dose cohorts achieved a complete response 8 of…
LOUISVILLE, Ky., July 07, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has added Augtyro™ (repotrectinib) manufactured…